Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Prospective, Multicenter, Randomized, Double-blind, Controlled Study to Evaluate the Efficacy and Safety of a Single Injection of Rexlemestrocel-L Combined With HA in Subjects With Moderate to Severe Chronic Low Back Pain

Trial Profile

A Prospective, Multicenter, Randomized, Double-blind, Controlled Study to Evaluate the Efficacy and Safety of a Single Injection of Rexlemestrocel-L Combined With HA in Subjects With Moderate to Severe Chronic Low Back Pain

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 11 Jul 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rexlemestrocel-L (Primary) ; Hyaluronic acid
  • Indications Back pain; Intervertebral disc degeneration
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms HyaluronicAcid
  • Sponsors Mesoblast

Most Recent Events

  • 26 Feb 2025 According to a Mesoblast media release, the capital raise concluded last month will facilitate expansion of sites enrolling in this CONFIRMATORY phase 3 trial and acceleration of patient accrual.
  • 21 Jul 2024 According to a Mesoblast media release, company announced patient enrollment commenced.
  • 18 Jul 2024 Planned End Date changed from 1 Aug 2027 to 1 Oct 2027.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top